Acceleron Pharma Inc  

(Public, NASDAQ:XLRN)   Watch this stock  
Find more results for GEORGE A. NADER�
41.01
-0.16 (-0.39%)
Mar 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.79 - 42.16
52 week 23.61 - 53.93
Open 40.92
Vol / Avg. 210,951.00/198,002.00
Mkt cap 1.34B
P/E     -
Div/yield     -
EPS -1.71
Shares 32.25M
Beta     -
Inst. own 96%
May 13, 2015
Q1 2015 Acceleron Pharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 20, 2015
Acceleron Pharma Inc at Biocentury Future Leaders in the Biotech Industry - 11:30AM EDT - Add to calendar
Mar 2, 2015
Acceleron Pharma Inc at Cowen Health Care Conference
Mar 2, 2015
Q4 2014 Acceleron Pharma Inc Earnings Release
Mar 2, 2015
Q4 2014 Acceleron Pharma Inc Earnings Call - Webcast
Feb 24, 2015
Acceleron Pharma Inc at RBC Healthcare Conference
Feb 23, 2015
Acceleron Pharma Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
Feb 11, 2015
Acceleron Pharma Inc at Leerink Global Healthcare Conference
Feb 3, 2015
Acceleron Pharma Inc at Canaccord Genuity Rare Disease, BioPharma One-on-One Day
Dec 10, 2014
Acceleron Pharma Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -227.25% -38.26%
Operating margin -324.71% 12.15%
EBITD margin - 13.75%
Return on average assets -15.40% -25.32%
Return on average equity -18.95% -
Employees 79 -
CDP Score - -

Address

128 SYDNEY STREET
CAMBRIDGE, MA 02139
United States - Map
+1-617-6499200 (Phone)
+1-617-6499988 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acceleron Pharma Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company�s research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

Officers and directors

JOHN L KNOPF Ph.D. President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Kevin F. McLaughlin Chief Financial Officer, Senior Vice President, Treasurer
Age: 54
Bio & Compensation  - Reuters
Steven D. Ertel Senior Vice President, Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
MATTHEW L SHERMAN M.D. Senior Vice President, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Ravindra Kumar Ph.D Chief Scientific Officer, Vice President
Age: 53
Bio & Compensation  - Reuters
John D. Quisel J.D., Ph.D. Vice President, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Terrence C. Kearney Director
Age: 59
Bio & Compensation  - Reuters
Francois Nader M.D., M.B.A Director
Age: 57
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 56
Bio & Compensation  - Reuters
George S. Golumbeski Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters